Elizabeth A. Mittendorf, MD, PhD
There is still a lot to be learned regarding the use of checkpoint inhibitors in breast cancer, but the field is advancing rapidly. Several agents have shown potential in recent trials.
, Mittendorf talked about checkpoint inhibition studies in TNBC, potential ways to make other subtypes more immunogenic to improve response, the role of PD-1, and what’s next in the field of immunotherapy in breast cancer.
OncLive: How has the use of checkpoint inhibition in breast cancer evolved in the past year?
: We have additional data now for multiple agents in TNBC; this time last year we just had pembrolizumab.
... to read the full story